OutlookAtomo continues to focus on core growth drivers,...

Outlook
Atomo continues to focus on core growth drivers, including:
* Obtaining regulatory approvals to facilitate commencement of device sales from key
international contracts with Access Bio and DIVOC Labs for North America and India,
respectively
* Pursuing opportunities in Australia for sale of a combination rapid COVID-19 screen
(both antigen and antibody testing) into the local market
* Continued scale up of business in the HIV self-test market and in particular, supporting
potential global tender opportunities being pursued by Atomo partner, Mylan
* Expansion of sales efforts related to OEM contracts, especially in North America to
existing and new OEM customers
* Developing and expanding new Atomo rapid diagnostic finished products and entry
into new point of care test markets, in partnership with certain existing customers in
strategic channels
* Launch of Atomo’s new digital health solutions that integrate with Atomo’s devices,
including a low-cost digital reader and a User App, to support the continued rollout of
rapid testing in community and consumer settings

65% up in revenue from last quarter is pretty good.